CEPHALON RECEIVES MARKETING APPROVAL FOR PROVIGIL MEDICATION FOR NARCOLEPSY (ABSTRACT)

Abstract:

Cephalon Inc. got its first U.S. drug approval from the FDA, for Provigil that treats narcolepsy. Provigil's generic name is modafinil and it is the first non-amphetamine drug for this use. The new drug is expected to sell about $100 million per year once pricing is set and it is in the pipeline for doctors to prescribe. Advantages of Provigil over amphetamines are that the drug more narrowly targets the parts of the brain needed to stimulate wakefulness; also, it won't have the addictive qualities. Myotrophin, a drug to treat Lou Gehrig's disease, would probably have been a more profitable drug for the company. (author)

Report Date: 1998-12-29
Authors:

0 Data & Analysis Center for Software



/